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1718evaluated pre-treatment with ticagrelor. So the only
randomized trial to evaluate pre-treatment is the
ACCOAST study, which showed harm and no beneﬁt to
the patients with pre-treatment.
Finally, despite the caveats of the CURE and
CREDO trials, which favor pretreatment without
really testing the hypothesis, when pooling the data
from ACCOAST, CURE, and CREDO trials (N > 18,000),
there was no decrease in mortality or ischemic
events, but a signiﬁcant 45% excess of major bleeding
with thienopyridine pre-treatment (3). Both clopi-
dogrel and pre-treatment are strategies of the past
(4). However, we encourage Dr. Lozano to perform
the study that he suggests in his conclusion.*Gilles Montalescot, MD, PhD
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Created EqualWe commend the authors of the recently published
ACCOAST-PCI (A Comparison of Prasugrel at the
Time of Percutaneous Coronary Intervention or as
Pre-treatment At the Time of Diagnosis in Patients
with Non-ST-Elevation Myocardial Infarction) study
(1) for their efforts. Despite being the largest
randomized trial of pre-treatment with prasugrelin non–ST-segment elevation myocardial infarction
(NSTEMI) patients, we have reservations that we
detail as follows.
Risk stratiﬁcation for adverse cardiac events is a key
component of treating NSTEMI patients. In this trial,
w57% of patients presentedwith ischemic ST-segment
changes and w23% with a GRACE (Global Registry of
Acute Coronary Events) score of more than 140. It
would be interesting to know the event rates in these
patients stratiﬁed according to whether they were
pre-treated with prasugrel or not. Ischemic events are
higher in patients with ischemic ST-segment changes
and/or high GRACE score, which may warrant more
aggressive therapy to improve outcomes (2).
The event rates for stent thrombosis were
extremely low, <0.5%. Because the trial was not
powered to show the differences between both
strategies, no real conclusions can be drawn about
stent thrombosis and the association with pre-
treatment with prasugrel other than numerically
there were fewer events in the pre-treatment group.*Ramez Nairooz, MD
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leagues, we have performed additional analyses of
the percutaneous coronary intervention subgroup
that need to be examined with caution considering
their post-hoc nature. Although it is possible to
evaluate the individual risk of a patient presenting
with a non–ST-segment elevation myocardial infarc-
tion according to well-known factors or scores, mak-
ing the decision to pre-treat or not, according to this
evaluation does not seem appropriate. The GRACE
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1719(Global Registry of Acute Coronary Events) score,
deﬁned as high when more than 110, was not associ-
ated with lower rates of the primary endpoint at 30
days in patients who were pre-treated with prasugrel
(15.66%) versus those who were not (14.08%, p value
for interaction ¼ 0.26). This was also conﬁrmed when
a GRACE score of more than 140 was considered
(15.54 pre-treatment vs. 16.85 no pretreatment, p for
interaction ¼ 0.56). The analyses were also consistent
according to the presence of ischemic abnormalities
on the electrocardiogram (p for interaction ¼ 0.74) or
for the presence of ST-segment depression more than
1 mm (p for interaction ¼ 0.97). The results were also
consistent at 7 days for all these subgroups.
Stent thrombosis rates were indeed very low and
not different between the 2 groups. These results are
in line with the TRITON (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet In-
hibition with Prasugrel) results and conﬁrm that
prasugrel is a very effective drug to prevent stent
thrombosis when administered in the catheterization
laboratory. The current data on stent thrombosis
support further the conclusions that prasugrel does
not need to be administered before coronary angiog-
raphy in NSTEMI patients.*Gilles Montalescot, MD, PhD
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